MCM
BIO icon

Matarin Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Matarin Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,246
Closed -$1.39M – 196
2015
Q1 		$1.39M Buy
+10,246
New +$1.27M 0.42% 115

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Matarin Capital Management's BIO Position: Q2 2015 in Review

Matarin Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2015, closing a stake of 10,246 shares — an estimated $1.39M sold.

Matarin Capital Management first reported a position in BIO in Q1 2015 and held it in 1 quarter. The position peaked at $1.39M in Q1 2015. 225 funds tracked by Wall St. Rank hold BIO as of Q2 2015.

  • Matarin Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2015 after selling out during the quarter.
  • Matarin Capital Management sold 10,246 Bio-Rad Laboratories Class A shares in Q2 2015, an estimated $1.39M.
  • Matarin Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2015 and held it in 1 quarter.
  • Matarin Capital Management's Bio-Rad Laboratories Class A position peaked at $1.39M in Q1 2015.
  • 225 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2015.

Based on Matarin Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.